LR-1111 is an analog of GBR-12935 that was discovered by Richard Rothman and co-workers in the 1990s. It differs from GBR-12935 in that the piperazine has been expanded to a homopiperazine (azepane) ring. LR-1111 is a dopamine reuptake inhibitor (DRI) with over 4000 times selectivity for the dopamine transporter (DAT) relative to the serotonin transporter (SERT) and the norepinephrine transporter (NET).